
Hansa Biopharma’s imlifidase advances to Phase III testing
According to Lund-based Hansa Biopharma AB the study protocol has been greenlighted both by the FDA and the European Medicines Agency (EMA), so its...

EMA delays Valneva vaccine approval
The CHMP’s action puts pressure on the French-Austrian vaccine developer, which wanted to market the vaccine from April on as the UK has already...

From waste to sugar - demonstration plant opens in Wales
The project’s 11-strong European consortium secured €7m funding from Circular bio-based Europe JU (formerly Bio Based Industries Joint Undertaking)...

Urovant Sciences cashes in $75m in licence deal from Pierre Fabre
Swiss Urovant Science, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., will receive up to USD $75m in upfront payment, regulatory, and sales...

AXA launches €440 m private equity healthcare strategy
The Strategy focuses specifically on companies in four core areas: medical devices, biopharmaceuticals, vaccines, and diagnostics. The...

French Ipsen falls after Epizyme take-over announcement
Even if Ipsen succeeds in halving the losses at Epizyme Inc, this would reduce the group's profit by nine percent by 2024, Credit Suisse analysts...

Ellipses Pharma licences SRB22 from SunRock Biopharma
Under the agreement, British Ellipses Pharma Ltd has been granted global rights to develop and commercialise SBR22 (which it renamed to EP0017) from...